SCHEMBL16437443

SCHEMBL16437443

CCc1c(Br)cnn1CC(=O)c1ccc(OC)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 3/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ MAPT P10636 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ PDE4D Q08499 1/20 0.44
▸ TSHR P16473 2/20 0.44
▸ CTNNB1 P35222 1/20 0.44
▸ WNT3A P56704 1/20 0.44
▸ HSD11B1 P28845 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ CYP3A4 P08684 3/20 0.43
▸ CYP2C19 P33261 3/20 0.43
▸ CYP2C9 P11712 2/20 0.43
▸ CYP1A2 P05177 2/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CBX7 O95931 1/20 0.42
▸ CDYL2 Q8N8U2 1/20 0.42
▸ CDYL Q9Y232 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16437438 0.87 PDE4B (0.52) PDE4BMAPTMEN1KMT2APDE4D
SCHEMBL28058790 0.83 PDE4B (0.48) PDE4BSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL16426964 0.83 PDE4B (0.48) PDE4BSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL16437437 0.77 PDE4B (0.51) PDE4BMAPTMEN1KMT2APDE4D
SCHEMBL16437441 0.76 PDE4D (0.55) PDE4BSMN1; SMN2MAPTPDE4DTSHR
SCHEMBL16426583 0.75 PDE4B (0.50) PDE4BMAPTMEN1KMT2ATSHR
SCHEMBL16427211 0.74 PDE4D (0.50) PDE4BSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL16437442 0.73 PDE4B (0.53) PDE4BSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL16427380 0.73 PDE4D (0.52) PDE4BSMN1; SMN2MAPTKMT2APDE4D
SCHEMBL19498643 0.72 CA12 (0.51) PDE4BMAPTMEN1KMT2APDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10005774-B2 Syk inhibitors GILEAD SCIENCES, INC. (US) 2018-06-26 — — US disclosed
US-20160368918-A1 SYK INHIBITORS Kronos Bio, Inc. 2016-12-22 — — US disclosed
US-9376441-B2 Substituted pyrrolidines as SYK inhibitors GILEAD SCIENCES, INC. (US) 2016-06-28 — — US disclosed
US-20150038488-A1 SYK INHIBITORS Kronos Bio, Inc. 2015-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038488-A1 SYK INHIBITORS SYK, BTK, LYN PDE4B 1658/4885SMN1; SMN2 3200/4885MAPT 4092/4885
US-20160368918-A1 SYK INHIBITORS SYK, BTK, LYN PDE4B 1728/4885SMN1; SMN2 3271/4885MAPT 4131/4885
US-10005774-B2 Syk inhibitors SYK, BTK, LYN PDE4B 1728/4885SMN1; SMN2 3271/4885MAPT 4131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback